Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease, dyslipidaemia, hypertension, obstructive or sleep apnoea (OSA).
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drug | In the three-year SURMOUNT-1 trial,
Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes
Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new results from a three-year trial.
Tirzepatide Demonstrates Long-Term Weight Reduction and Diabetes Risk Reduction in Obesity and Prediabetes: NEJM
Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a previous analysis of the SURMOUNT-1 trial, tirzepatide pro
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results suggest that tirzepatide - the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound - could prevent one new case of diabetes for every nine patients treated.
Medscape1d
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
TCTMD20h
SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Medpage Today on MSN1d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults
In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure ...
The American Journal of Managed Care1d
For Obesity and HFpEF, Tirzepatide Cuts Risk of CV Death or Worsening HF by 38%
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...
Futurism on MSN1d
Mounjaro Appears to Be Extremely Effective at Preventing Diabetes
A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...
Becker's Hospital Review3d
Mounjaro lowers Type 2 diabetes risk in phase 3 trial: Study
A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...